The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Self-citationRecognition of Stress-Induced MHC Molecules by Intestinal Epithelial γδ T Cells
Groh, V., Steinle, A., Bauer, S., & Spies, T. (1998) · Science · doi:10.1126/science.279.5357.1737 · Cited by 1,142
Self-citationRae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
An Activating Immunoreceptor Complex Formed by NKG2D and DAP10
Wu, J., Song, Y., Bakker, A. B. H., Bauer, S., Spies, T., Lanier, L. L., & Phillips, J. H. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,039
Self-citationBroad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Self-citationGroh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
Self-citationCostimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R., & Spies, T. (2001) · Nature Immunology · doi:10.1038/85321 · Cited by 951
Self-citationCerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
Schatz, P. J. (1993) · Nature Biotechnology · doi:10.1038/nbt1093-1138 · Cited by 580
Steinle, A., Li, P., Morris, D. L., Groh, V., Lanier, L. L., Strong, R. K., & Spies, T. (2001) · Immunogenetics · doi:10.1007/s002510100325 · Cited by 454
Self-citation
Cited by
Items 101–134 of 134
The Role of Natural Killer Cells in Autoimmune Diseases
Kucuksezer, U. C., Aktas Cetin, E., Esen, F., Tahrali, I., Akdeniz, N., Gelmez, M. Y., & Deniz, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622306 · Cited by 284
NKG2D: A Master Regulator of Immune Cell Responsiveness
Wensveen, F. M., Jelenčić, V., & Polić, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00441 · Cited by 271
“As a result, activated T cells become less responsive to NKG2D (co-) stimulation (50).”
BackgroundInfluentialSurface NK receptors and their ligands on tumor cells
Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M. C., & Moretta, A. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.002 · Cited by 283
Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions
Zingoni, A., Sornasse, T., Cocks, B. G., Tanaka, Y., Santoni, A., & Lanier, L. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3716 · Cited by 283
Balsamo, M., Manzini, C., Pietra, G., Raggi, F., Blengio, F., Mingari, M. C., Varesio, L., Moretta, L., Bosco, M. C., & Vitale, M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343448 · Cited by 282
Dunn, C., Chalupny, N. J., Sutherland, C. L., Dosch, S., Sivakumar, P. V., Johnson, D. C., & Cosman, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022059 · Cited by 280
KIR and disease: a model system or system of models?
Khakoo, S. I., & Carrington, M. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00459.x · Cited by 280
Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor
Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B., Bando, J. K., Kim, A. H., Walker, J., Andahazy, M., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.037 · Cited by 280
Impairment of NK Cell Function by NKG2D Modulation in NOD Mice
Ogasawara, K., Hamerman, J. A., Hsin, H., Chikuma, S., Bour-Jordan, H., Chen, T., Pertel, T., Carnaud, C., Bluestone, J. A., & Lanier, L. L. (2003) · Immunity · doi:10.1016/s1074-7613(02)00505-8 · Cited by 276
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani-Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271
NK cells and ILCs in tumor immunotherapy
Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 270
Zaenker, P., Gray, E. S., & Ziman, M. R. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.017 · Cited by 267
Strid, J., Roberts, S. J., Filler, R. B., Lewis, J. M., Kwong, B. Y., Schpero, W., Kaplan, D. H., Hayday, A. C., & Girardi, M. (2008) · Nature Immunology · doi:10.1038/ni1556 · Cited by 266
Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma
Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D., Steinle, A., Ferrone, S., & Pistoia, V. (2004) · Neoplasia · doi:10.1593/neo.04316 · Cited by 264
Zhang, P., Su, D.-M., Liang, M., & Fu, J. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.08.013 · Cited by 263
Skov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Deng, W., Gowen, B. G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T. L., Xiong, N., & Raulet, D. H. (2015) · Science · doi:10.1126/science.1258867 · Cited by 255
Cellular ligands of activating NK receptors
Bottino, C., Castriconi, R., Moretta, L., & Moretta, A. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.02.007 · Cited by 255
NKG2D and Its Ligands: “One for All, All for One”
Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., & Santoni, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00476 · Cited by 254
Parihar, R., Rivas, C., Huynh, M., Omer, B., Lapteva, N., Metelitsa, L. S., Gottschalk, S. M., & Rooney, C. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0572 · Cited by 254
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238
Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3211 · Cited by 221
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218
McGilvray, R. W., Eagle, R. A., Watson, N. F. S., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0991 · Cited by 196
Barsoum, I. B., Hamilton, T. K., Li, X., Cotechini, T., Miles, E. A., Siemens, D. R., & Graham, C. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2104 · Cited by 188
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
Self-citationImpairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149
“While some studies also report down-modulation of surface NKG2D on cytotoxic lymphocytes through sNKG2DL-mediated internalization (91, 92), other studies were unable to confirm these findings or attributed NKG2D down-modulation instead to TGF-β (82, 93, 94).”
ResultAblation of Cbl-b provides protection against transplanted and spontaneous tumors
Chiang, J. Y., Jang, I. K., Hodes, R., & Gu, H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29472 · Cited by 124
Sène, D., Levasseur, F., Abel, M., Lambert, M., Camous, X., Hernandez, C., Pène, V., Rosenberg, A. R., Jouvin-Marche, E., Marche, P. N., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001184 · Cited by 113
“Soluble TGFb is associated with NKG2D reduction Systemic NKG2D downregulation on immune effector cells has been related to the release of soluble factors such as MIC molecules (sMIC) in the serum of cancer patients [13].”
Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680546 · Cited by 93
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells
Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000233 · Cited by 29
Metadata
- Authors
- Groh, V., Wu, J., Yee, C., & Spies, T.
- Venue
- Nature
- Published
- 2002-10
- Volume
- 419
- Issue
- 6908
- Pages
- 734-738
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2064920472
- Cited by
- 1,592
- References
- 19
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.